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Mineralocorticoid receptor antagonists: The evolution of utility physiological stimuli, the most important of which are
and pharmacology. For more than 30 years after the discovery angiotensin II (Ang II), potassium ions, and adrenalcor-
of aldosterone, scientists believed that its sole site of action ticoid hormone (ACTH) [1]. In addition to the adrenalwas at epithelial tissues, most notably the kidney, where it
gland, recent research using reverse transcription-poly-mediated the transport of Na and K. It was soon recognized
merase chain reaction (RT-PCR) has indicated that thealdosterone contributed to several diseases by causing edema.
Armed with this information, scientists set out more than 30 vasculature [2] and the myocardium [3], as well as the
years ago to develop an antagonist of the mineralocorticoid mineralocorticoid receptor may possess the necessary bio-
receptor for the treatment of edematous states. From this ef- chemical machinery for aldosterone biosynthesis [4, 5].fort, spironolactone (Aldactonet) was discovered. Spironolac-
However, the physiological significance of nonadrenaltone acts functionally as a competitive inhibitor of the mineral-
aldosterone synthesis is controversial.ocorticoid (aldosterone) receptor, and although spironolactone
is an effective mineralocorticoid receptor antagonist, it is not Classically, aldosterone has been thought to act at the
without limitations. These limitations include unwanted pro- kidney, where it regulates the absorption of Na and water
gestational and antiadrogenic side effects that limit its use in
and the excretion of K in normal physiology, and canthe chronic treatment of disease. In addition to its actions at
mediate edema in numerous disease states. However,the collecting tubule, aldosterone can participate in pathophysi-
ology by actions at the heart, vasculature, and kidney, and it much data have accumulated over the last 10 to 15 years
is likely that the most significant contributions to cardiovascular demonstrating that aldosterone plays a significant role
disease are due to actions at these sites rather than those related in extrarenal mechanisms of pathophysiology. These in-
to Na and water retention. This is underscored by the recent
teresting studies underscore a shift in paradigm in theclinical results from the RALES-004 Trial in which treatment
field of aldosterone research: the actions of aldosteronewith Aldactone demonstrated a significant benefit on mortality
in patients with severe heart failure. The limited utility of are not limited to effects on ion transport in epithelial
spironolactone owing to the aforementioned steroid-related tissue, but rather the important role in disease is aldoste-
side effects has been especially frustrating, given the newly rone in nonepithelial tissues (Fig. 1).recognized role of aldosterone in cardiovascular disease. To
The first evidence that aldosterone may play an impor-obviate these limitations, eplerenone is currently being devel-
tant role in nonepithelial actions of disease was that ofoped by Searle. Eplerenone is a competitive antagonist of the
mineralocorticoid receptor that takes advantage of replacing Brilla and Weber. These scientists first demonstrated
the 17a-thoacetyl group of spironolactone with a carbomethoxy that elevated levels of aldosterone, in combination with
group, conferring excellent selectivity for the mineralocorticoid a high-sodium diet, result in interstitial cardiac fibrosisreceptor over other steroid receptors. The pharmacological
[6]. In these landmark studies, it was shown that theprofile of eplerenone positions it to be an effective and selective
effect was independent of elevated blood pressure, sincemineralocorticoid receptor antagonist.
increased collagen deposition was also observed in the
right ventricle. These findings have since been corrobo-
The classic site of aldosterone synthesis is in mitochon- rated and extended by the laboratories of Young and
dria of the zona glomerulosa cells of the adrenal gland, Funder [7] and Robert et al [8]. Apparently, elevated
whereby cholesterol is converted to pregnenolone, which plasma levels are not a prerequisite for aldosterone to
is subsequently converted by a series of enzymes to pro- mediate fibrosis. Recent data from Sylvestre et al demon-
gesterone, deoxycorticosterone, corticosterone, and fi- strate that the nonselective aldosterone receptor antago-
nally aldosterone. The synthesis is regulated by several nist spironolactone can effectively attenuate reactive fi-
brosis in the viable myocardium of the postinfarcted left
ventricle of the rat [9]. More recently, studies using theKey words: aldosterone, spironolactone, eplerenone, sodium and K
transport, edema. selective aldosterone receptor antagonist eplerenone
confirm and extend these findings by showing thatÓ 2000 by the International Society of Nephrology
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Fig. 1. Contemporary model of the role of al-
dosterone in cardiovascular pathophysiology.
The model underscores the importance of non-
renal mechanisms of aldosterone in disease.
blocking the mineralocorticoid receptor in the postmyo- thology in this model (abstract; Rocha et al, Am J Hyper-
tens 6:103A, 1998). In this investigation, it was demon-cardial infarcted rat heart can attenuate left ventricular
remodeling in addition to reducing reactive fibrosis (ab- strated that animals treated with ACE inhibitor were
protected, but the pathology could be re-established withstract; Delyani et al, Eur Heart J 20:613, 1999). These
are important findings because the rat model of postmyo- subcutaneous administration of Ang II, demonstrating
that the protective effect of the ACE inhibitor was duecardial infarction is not characterized by elevated plasma
aldosterone levels. Thus, the efficacy of aldosterone re- to the effects on the production of Ang II and not due
to other pharmacological effects of ACE inhibition.ceptor antagonism suggests that either local aldosterone
production contributes to cardiac pathophysiology, the However, if the ACE inhibitor-treated, Ang II-infused
rats were adrenalectomized or treated with eplerenone,injured tissue is somehow sensitized to aldosterone possi-
bly via increased receptor numbers, or a combination of protection was afforded equal to that of ACE inhibitor
treatment, indicating that Ang II per se is not sufficientthe these two mechanisms is at play.
In addition to reports demonstrating that aldosterone to cause vascular and glomerular damage and that aldo-
sterone plays a central role in the pathology.can contribute to interstitial cardiac fibrosis, studies have
also reported that aldosterone can mediate vascular fi- Aldosterone has also been postulated to contribute to
prothrombotic conditions. Brown et al have reportedbrosis of cardiac arterioles [6, 7] and large arteries. Stud-
ies by Benetos, Lacolley, and Safar have demonstrated that aldosterone correlates well with plasminogen activa-
tor inhibitor-1 (PAI-1) levels in patients [14]. These datathat aldosterone receptor antagonism can reduce aortic
fibrosis and improve vascular compliance in the sponta- indicate that aldosterone may upset the homeostatic bal-
ance and promote prothrombotic conditions, potentiallyneously hypertensive rat, a model characterized by nor-
moaldosteronemia, again demonstrating that aldoste- increasing the risk for acute myocardial infarction. Stud-
ies demonstrating that aldosterone can indeed increaserone can play a pathophysiological role even when
plasma levels are in the normal range [10]. PAI-1 levels and that the clinical observation is not an
epiphenomenon are needed.In addition to the heart, the kidney has also been
identified as a target organ of aldosterone-mediated pa- Given the new appreciation for aldosterone in cardio-
vascular disease, it is evident that a means to abrogatethology. The spontaneously hypertensive stroke-prone
rat is characterized by activation of the renin-angioten- these pathophysiological effects is clinically important.
Since aldosterone is the terminal hormone in the RAASsin-aldosterone system (RAAS), severe hypertension,
renal pathology, and early mortality from cerebral hem- system, it was assumed that agents that interrupted this
humoral system proximal, such as ACE inhibitors ororrhage. Angiotensin-converting enzyme (ACE) inhibi-
tors [11] and angiotensin type 1 (AT1) [12] receptor an- blocking AT1 receptors, would serve this purpose. ACE
inhibitors block the formation of Ang II, a primary stimu-tagonists have been shown to attenuate renal and
cerebral pathology. More recent studies have revealed lus for aldosterone secretion, by inhibiting the conver-
sion of Ang I to Ang II. Despite inhibition of Ang IIthat aldosterone receptor antagonist can also protect
against end organ damage [13]. Rocha et al have recently production, there are several reports that a phenomenon
referred to as “aldosterone synthesis escape” occurs dur-implicated aldosterone as the primary mediator of pa-
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ing ACE inhibition, a topic that has been reviewed re- field of nonepithelial effects of aldosterone stimulated
the development of a superior agent to treat aldosterone-cently [15]. Briefly, aldosterone synthesis escape refers
to the observation that ACE inhibitors reduce plasma mediated pathology. A new aldosterone receptor antag-
onist, eplerenone, is currently in development by G.D.aldosterone levels acutely, only for levels to return to
and often exceed pretreatment values during chronic Searle. Like spironolactone, it is a competitive antagonist
of the aldosterone receptor. It is a molecule that takestreatment. In addition to ACE inhibitors, a recent report
has shown that aldosterone synthesis escape occurs dur- advantage of replacing the 17a-thoacetyl group of spiro-
nolactone with a carbomethoxy group. This confers ex-ing AT1 receptor blockade as well (abstract; Yusuf et al,
Circulation 96:I452, 1997). cellent selectivity for the aldosterone receptor over other
steroid receptors. In addition, this chemical substitution
produces a molecule that has negligible activity at the cyto-
EVOLUTION OF PHARMACOLOGY
chrome p-450 enzyme of endocrine organs. The pharmaco-
Given the vast role of aldosterone in the cardiovascu- logical profile of eplerenone positions it to be an effective
lar disease, it is essential to have pharmacological agents and selective agent. It has a half-life of approximately
that mitigate its effects. After the isolation and identifi- 3.5 hours in humans and does not produce any pharmaco-
cation of aldosterone as a physiologically important min- logically important metabolites. In vitro receptor binding
eralocorticoid, it was obvious that this hormone may studies have revealed that its affinity is approximately 10-
play an important role in edematous disease states. To to 20-fold less than spironolactone for the aldosterone
block its actions, the compound spironolactone was syn- receptor [22]. However, unlike spironolactone, eplere-
thesized over 30 years ago [16]. Spironolactone, a prod- none has little affinity for other steroid receptors. Al-
uct of G.D. Searle, is presently the only therapeutic prod- though eplerenone has a lower in vitro aldosterone re-
uct available to combat the pathological effects of ceptor affinity than spironolactone, both compounds
hyperaldosteronism directly, although a new aldosterone show similar efficacy in blocking the aldosterone-medi-
receptor antagonist is in development (discussed later in ated changes in urinary Na:K ratio in the rat Kagawa
this article). Spironolactone is a competitive antagonist of bioassay (abstract; Delyani et al, Am J Hypertens 11:94A,
the aldosterone receptor and the active component of 1998), as well as in human studies (unpublished data).
Aldactonet. It has a structure similar to that of other The discrepancy of in vitro and in vivo pharmacological
steroids with a lactone ring as a substituent at C-17. properties appears to be, in part, caused by the less avid
Spironolactone is rapidly cleared, exhibiting a half-life binding of eplerenone to plasma proteins compared with
of less than 10 minutes in animal studies [17] and has spironolactone, as well as a temperature-related effect
similar rapid clearance in humans [18]. However, spiro- specific to the receptor-binding assay. Recent evidence
nolactone is metabolized to several active metabolites. has also demonstrated that eplerenone has antifibrotic
Canrenoate and canrenone are the chief metabolites and effects in animals comparable to those of spironolactone
the most pharmacologically important. Both of these (abstract; Frierdich et al, Am J Hypertens 11:94A, 1998).
metabolites exist in equilibrium and have half-lives that Toxicological studies performed to date indicate that
are between 17 and 22 hours [18–20]. Spironolactone there are no steroid-related adverse effects, genotoxic
has good oral bioavailability (approximately 90%) [21] nor clastogenic effects associated with eplerenone. The
and lacks a clinically important first pass liver effect compound is currently in phase III clinical trials. Results
[18]. Spironolactone is used in the treatment of several from phase I trials indicated that the compound has a
diseases, but most commonly hypertension. When spiro- good safety profile and is effective in reversing aldoste-
nolactone was developed nearly 30 years ago, the scien- rone-mediated changes in urinary electrolytes. Phase II
tific study of aldosterone was limited to effects on epithe- results suggested that eplerenone will prove effective in
lial ion transport, and even this knowledge was in its the treatment of hypertension as well as heart failure.
infancy. As a result, spironolactone was classified as a
potassium-sparing diuretic. Given that the compelling
CONCLUSIONevidence of the role of aldosterone in the pathophysiol-
ogy of cardiovascular disease extends beyond ion trans- Recent data implicate aldosterone as an important
contributor to cardiovascular disease. Moreover, theport, this classification is presently obsolete.
Although spironolactone is an effective aldosterone mechanism by which aldosterone participates in disease
is unlikely to be limited to the effects on ion flux at epi-receptor antagonist, it is not without limitations, which
include progestational and anti-androgenic side effects. thelial tissues, but rather to nonepithelial sites. Numer-
ous studies have implicated aldosterone in cardiac andThese are most commonly manifested as gynecomastia,
abnormal menstrual cycles, and impotence, which limit vascular fibrosis, renal disease, and thrombogenic condi-
tions. To combat these effects, two aldosterone receptorits use by physicians in the chronic treatment of disease.
In addition to the issue of side effects, the burgeoning antagonists exist. The first, spironolactone, although an
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7. Young M, Funder J: Determinants of cardiac fibrosis in experi-effective aldosterone receptor antagonist, has adverse
mental hypermineralocorticoid states. Am J Physiol 269:E657–
steroid-related side effects associated with its use, which E662, 1995
8. Robert V, Ven Thiem N, Cheav SL, Mouas CB, Swynghedauwlimits its utility. The second receptor antagonist, eplere-
Delcayre C: Increased cardiac types I and III collagen mRNAsnone, has similar in vivo efficacy as spironolactone but
in aldosterone-salt hypertension. Hypertension 24:30–36
minimal side effects, making it an effective and selective 9. Silvestre J, Heymes C, Abdeslam O, Valerie R, Carayon A,
Aupetit-Faisant, B, Swynghedauw B, Delcayre C: Activationanti-aldosterone agent.
of cardiac aldosterone production in rat myocardial infarction:The most significant evidence for the role of aldoste-
Effect of angiotension II receptor blockade and role in cardiac
rone in cardiac pathophysiology is the recent publication fibrosis. Circulation 99(20):2694–2701, 1999
10. Benetos A, Lacolley P, Safar ME: Prevention of aortic fibrosisof the RALES-004 study [23]. In this study, patients with
by spironolactone in spontaneously hypertensive rats. ArteriosclerNYHA class III and IV heart failure were treated with 25
Thromb Vasc Biol 17:1152–1156, 1997
mg of the nonselective aldosterone receptor antagonist, 11. Stier CT, Chander P, Gustein WH, Levine S, Itskovitz HD:
Therapeutic benefit of captopril in salt-loaded stroke-prone spon-spironolactone, or placebo in addition to standard of
taneously hypertensive rats is independent of hypotensive effect.care, which included ACE inhibitors, digitalis, and di-
Am J Hypertens 4:680–687, 1991
uretics. The study was terminated early due to a highly 12. Stier CT, Adler LA, Levine S, Chander P: Stroke prevention
by losartan in stroke-prone spontaneously hypertensive rats. J Hy-significant benefit of spironolactone on mortality (30%
pertens 11:S37–S42, 1993reduction vs. placebo). These data are especially striking
13. Rocha R, Chander C, Khanna K, Zuckerman A, Stier C: Miner-
in light of the use of both ACE inhibitors and diuretics, alocorticoid blockade reduces vascular injury in stroke-prone hy-
pertensive rats. Hypertension 31:451–458, 1998as well as the relatively low dose of spironolactone. The
14. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR,low dose of spironolactone used also suggests that the
Vaughan DE: Effect of activation and inhibition of the renin-
beneficial effect of aldosterone receptor blockade was angiotensin system on plasma PAI-I. Hypertension 32:965–971,
1998not due to a hemodynamic effect nor can it be explained
15. Struthers A: Aldosterone escape during angiotensin convertingby diuresis. Future studies using the selective aldosterone
enzyme inhibition therapy in chronic heart failure. J Cardiovasc
receptor antagonist eplerenone will hopefully reveal the Fail 2:47–54, 1996
16. Sadee W, Riegelman S, Jones S: Disposition of tritium-labeledmechanisms underlying these remarkable results.
spironolactone in the dog. J Pharm Sci 61:1132–1135, 1972
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